{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:45:58Z","timestamp":1773157558280,"version":"3.50.1"},"reference-count":51,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"100th Anniversary Chulalongkorn University Fund for Doctoral Scholarship"},{"name":"90th Anniversary Chulalongkorn University Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Animals"],"abstract":"<jats:p>Fosfomycin is a bactericidal drug recommended as an alternative treatment for canine bacterial cystitis, particularly in cases involving multidrug-resistant (MDR) infections when no other options are available. In this study, minimum inhibitory concentration (MIC) and mutant prevention concentration (MPC) of fosfomycin were determined against 79 clinical E. coli isolates using the agar dilution method. The susceptibility rate of E. coli to fosfomycin was 86.06%, with MIC50 and MIC90 values of 4 mg\/L and 96 mg\/L, respectively. MPC50 and MPC90 values were 64 mg\/L and 192 mg\/L. Using pharmacokinetic (PK) data from dogs given a single 80 mg\/kg oral dose of fosfomycin, the area under the curve per MIC50 (AUC0\u201324\/MIC50) was 85.79 with time above MIC50 (T &gt; MIC50) exceeding 50%. In urine, the AUC0\u201324\/MIC50 was 10,694.78, and the AUC0\u201324\/MPC90 was 222.81, with T &gt; MPC90 extending beyond 24 h. Therefore, fosfomycin exhibited significant antibacterial activity against canine uropathogenic E. coli, including MDR strains, at concentrations below the susceptible MIC breakpoint. However, the high MPC values, especially the MPC90, indicate the critical importance of performing susceptibility testing for fosfomycin and maintaining ongoing resistance monitoring.<\/jats:p>","DOI":"10.3390\/ani14131916","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T04:53:27Z","timestamp":1719809607000},"page":"1916","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["In Vitro Antibacterial Activities of Fosfomycin against Escherichia coli Isolates from Canine Urinary Tract Infection"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0363-2470","authenticated-orcid":false,"given":"Nattha","family":"Jariyapamornkoon","sequence":"first","affiliation":[{"name":"Graduate Program in Veterinary Bioscience, Faculty of Veterinary Science, Chulalongkorn University, Bangkok 10330, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2790-1100","authenticated-orcid":false,"given":"Suphachai","family":"Nuanualsuwan","sequence":"additional","affiliation":[{"name":"Department of Veterinary Public Health, Faculty of Veterinary Sciences, Chulalongkorn University, Bangkok 10330, Thailand"},{"name":"Center of Excellence for Food and Water Risk Analysis (FAWRA), Department of Veterinary Public Health, Faculty of Veterinary Science, Chulalongkorn University, Bangkok 10330, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8116-4602","authenticated-orcid":false,"given":"Nipattra","family":"Suanpairintr","sequence":"additional","affiliation":[{"name":"Center of Excellence for Food and Water Risk Analysis (FAWRA), Department of Veterinary Public Health, Faculty of Veterinary Science, Chulalongkorn University, Bangkok 10330, Thailand"},{"name":"Department of Pharmacology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok 10330, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/jac\/dkv157","article-title":"Reviving old antibiotics","volume":"70","author":"Theuretzbacher","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Cassir, N., Rolain, J.-M., and Brouqui, P. (2014). A new strategy to fight antimicrobial resistance: The revival of old antibiotics. Front. Microbiol., 5.","DOI":"10.3389\/fmicb.2014.00551"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/phar.2780","article-title":"New ways of using old antibiotics in pediatrics: Focus on fosfomycin","volume":"43","author":"Tran","year":"2023","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_4","first-page":"985","article-title":"Antimicrobial resistance and prevalence of canine uropathogens at the Western College of Veterinary Medicine Veterinary Teaching Hospital, 2002\u20132007","volume":"49","author":"Ball","year":"2008","journal-title":"Can. Vet. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/jvim.13571","article-title":"Antimicrobial Susceptibility Patterns in Urinary Tract Infections in Dogs (2010\u20132013)","volume":"29","author":"Wong","year":"2015","journal-title":"J. Vet. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1939-1676.2001.tb02327.x","article-title":"Interrelations of organism prevalence, specimen collection method, and host age, sex, and breed among 8,354 canine urinary tract infections (1969\u20131995)","volume":"15","author":"Ling","year":"2001","journal-title":"J. Vet. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tvjl.2019.02.008","article-title":"International Society for Companion Animal Infectious Diseases (ISCAID) guidelines for the diagnosis and management of bacterial urinary tract infections in dogs and cats","volume":"247","author":"Weese","year":"2019","journal-title":"Vet. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jgar.2018.01.011","article-title":"Antimicrobial susceptibility survey on bacterial agents of canine and feline urinary tract infections: Weight of the empirical treatment","volume":"13","author":"Rampacci","year":"2018","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0924-8579(03)00230-9","article-title":"In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance","volume":"22","author":"Marchese","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000239140","article-title":"Pharmacokinetic profile of fosfomycin trometamol","volume":"39","author":"Bergan","year":"1993","journal-title":"Chemotherapy"},{"key":"ref_11","unstructured":"Boothe, D.M. (2012). Small Animal Clinical Pharmacology & Therapeutics, Elsevier Health Sciences. [2nd ed.]."},{"key":"ref_12","unstructured":"USFDA (2024, May 19). MONUROL (Fosfomycin Tromethamine) Sachet, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050717s005lbl.pdf."},{"key":"ref_13","unstructured":"WHO (2024, May 19). Critically Important Antimicrobials for Human Medicine, Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/312266\/9789241515528-eng.pdf."},{"key":"ref_14","unstructured":"EMA (2024, May 19). Categorisation of Antibiotics in the European Union, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/report\/categorisation-antibiotics-european-union-answer-request-european-commission-updating-scientific_en.pdf."},{"key":"ref_15","unstructured":"Plumb, D.C. (2018). Plumb\u2019s Veterinary Drug Handbook, John Wiley & Sons. [9th ed.]."},{"key":"ref_16","unstructured":"Papich, M.G. (2016). Saunders Handbook of Veterinary Drugs: Small and Large Animal, Elsevier Health Sciences. [4th ed.]."},{"key":"ref_17","unstructured":"CLSI (2021). Performance Standards for Antimicrobial Susceptibility Testing, CLSI. [31st ed.]. CLSI Supplement M100."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jac\/dkg269","article-title":"The mutant selection window and antimicrobial resistance","volume":"52","author":"Drlica","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10156-006-0499-Y","article-title":"Time courses of bacterial density in urine during antibacterial chemotherapy and influential factors in patients having positive bacteriuria with a complicated urinary tract","volume":"13","author":"Matsukawa","year":"2007","journal-title":"J. Infect. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.urology.2015.04.002","article-title":"Intracellular Bacterial Communities: A Potential Etiology for Chronic Lower Urinary Tract Symptoms","volume":"86","author":"Scott","year":"2015","journal-title":"Urology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-3164.2009.00856.x","article-title":"New concepts in antimicrobial susceptibility testing: The mutant prevention concentration and mutant selection window approach","volume":"20","author":"Blondeau","year":"2009","journal-title":"Vet. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1128\/AAC.43.7.1756","article-title":"Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus","volume":"43","author":"Dong","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1128\/AAC.45.2.433-438.2001","article-title":"Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae","volume":"45","author":"Blondeau","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1120009X.2004.11782371","article-title":"The Role of PK\/PD Parameters to Avoid Selection and Increase of Resistance: Mutant Prevention Concentration","volume":"16","author":"Blondeau","year":"2004","journal-title":"J. Chemother."},{"key":"ref_25","unstructured":"CLSI (2024). Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals, CLSI. [7th ed.]. CLSI Supplement VET01S."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2009.10.019","article-title":"Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin","volume":"35","author":"Falagas","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1086\/528867","article-title":"Pandrug Resistance (PDR), Extensive Drug Resistance (XDR), and Multidrug Resistance (MDR) among Gram-Negative Bacilli: Need for International Harmonization in Terminology","volume":"46","author":"Falagas","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/jac\/dki136","article-title":"Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli","volume":"55","author":"Marcusson","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Jariyapamornkoon, N., Patthanachai, K., and Suanpairintr, N. (2023). Plasma and Urine Pharmacokinetics of Oral Fosfomycin Tromethamine in Dogs. Vet. Sci., 10.","DOI":"10.3390\/vetsci10060391"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zhang, L., Xie, H., Wang, Y., Wang, H., Hu, J., and Zhang, G. (2022). Pharmacodynamic Parameters of Pharmacokinetic\/Pharmacodynamic (PK\/PD) Integration Models. Front. Vet. Sci., 9.","DOI":"10.3389\/fvets.2022.860472"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: An update","volume":"55","author":"Mouton","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.vetmic.2013.12.021","article-title":"Pharmacokinetic-pharmacodynamic (PK-PD) modeling and the rational selection of dosage regimes for the prudent use of antimicrobial drugs","volume":"171","author":"Papich","year":"2014","journal-title":"Vet. Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0034-5288(02)00039-5","article-title":"The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics","volume":"73","author":"Toutain","year":"2002","journal-title":"Res. Vet. Sci."},{"key":"ref_35","first-page":"25","article-title":"Categorization of antimicrobial agents prescribed inthe Veterinary Teaching Hospital in Thailand","volume":"12","author":"Leesombun","year":"2019","journal-title":"J. Appl. Anim. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.vetmic.2010.10.025","article-title":"In vitro susceptibility of canine and feline Escherichia coli to fosfomycin","volume":"149","author":"Hubka","year":"2011","journal-title":"Vet. Microbiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2478\/cipms-2023-0037","article-title":"Fosfomycin activity against strains isolated from urine specimens","volume":"36","author":"Zdzieblo","year":"2023","journal-title":"Curr. Issues Pharm. Med. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/jac\/dkad147","article-title":"Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: A post hoc analysis of the FOREST randomized trial","volume":"78","author":"Bereciartua","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/jac\/dkz519","article-title":"Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections","volume":"75","author":"Abbott","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ja.2016.124","article-title":"Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: An in vitro and in vivo comparative study","volume":"70","author":"Pan","year":"2017","journal-title":"J. Antibiot."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1128\/AAC.50.1.403-404.2006","article-title":"Low correlation between MIC and mutant prevention concentration","volume":"50","author":"Drlica","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Gianvecchio, C., Lozano, N.A., Henderson, C., Kalhori, P., Bullivant, A., Valencia, A., Su, L., Bello, G., Wong, M., and Cook, E. (2019). Variation in Mutant Prevention Concentrations. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.00042"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jac\/dkp282","article-title":"Antibacterial activities of a fosfomycin\/tobramycin combination: A novel inhaled antibiotic for bronchiectasis","volume":"64","author":"MacLeod","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1128\/AAC.05958-11","article-title":"Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa","volume":"56","author":"MacLeod","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.ijantimicag.2006.05.019","article-title":"Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections","volume":"28","author":"Mazzei","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1128\/AAC.02099-12","article-title":"Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents","volume":"57","author":"Descourouez","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Petek, M., Baebler, S., Kuzman, D., Rotter, A., Podlesek, Z., Gruden, K., Ravnikar, M., and Urleb, U. (2010). Revealing fosfomycin primary effect on Staphylococcus aureus transcriptome: Modulation of cell envelope biosynthesis and phosphoenolpyruvate induced starvation. BMC Microbiol., 10.","DOI":"10.1186\/1471-2180-10-159"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1089\/mdr.2022.0119","article-title":"Investigations on In Vivo Pharmacokinetic\/Pharmacodynamic Determinants of Fosfomycin in Murine Thigh and Kidney Infection Models","volume":"29","author":"Chavan","year":"2022","journal-title":"Microb. Drug Resist."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Lepak, A.J., Zhao, M., VanScoy, B., Taylor, D.S., Ellis-Grosse, E., Ambrose, P.G., and Andes, D.R. (2017). In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 1\u201311.","DOI":"10.1128\/AAC.00476-17"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.00752-15","article-title":"Pharmacodynamics of fosfomycin: Insights into clinical use for antimicrobial resistance","volume":"59","author":"Drusano","year":"2015","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Animals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2615\/14\/13\/1916\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:07:11Z","timestamp":1760108831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2615\/14\/13\/1916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":51,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ani14131916"],"URL":"https:\/\/doi.org\/10.3390\/ani14131916","relation":{},"ISSN":["2076-2615"],"issn-type":[{"value":"2076-2615","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}